Prostatic Neoplasms Recruiting Phase 2 Trials for Pembrolizumab (DB09037)

Also known as: Neoplasm,Prostatic / Neoplasms, Prostatic / Prostatic Neoplasm

IndicationStatusPhase
DBCOND0028225 (Prostatic Neoplasms)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03007732Pembrolizumab in Combination With Intratumoral SD-101 TherapyTreatment